Nrf2 modulators, mainly activators, have been already demonstrated to elicit beneficial effects in models of different human pathologies, such as cancer, autoimmune diseases, liver, kidney, and lung diseases, as well as common neurodegenerative disorders (Adelusi et al., 2020; Panieri et al., 2020; Scuderi et al., 2020; Sharma et al., 2020; Kim, 2021; Kourakis et al., 2021; Sezgin-Bayindir et al., 2021; Telkoparan-Akillilar et al., 2021; Zhao et al., 2021). Here, NFE2L2 is linked to cancer.